Angela Zambrano

Dr. Angela Zambrano

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
LPLuis Gabriel Parra-Lara
Luis Gabriel Parra-Lara
DMDiana M. Mendoza-Urbano
Diana M. Mendoza-Urbano
JBJuan C. Bravo
Juan C. Bravo
Constain Hugo SalamancaConstain Hugo Salamanca
Constain Hugo Salamanca
AZAngela Zambrano
Angela Zambrano
Coffee is the second most popular drink worldwide, and it has various components with antioxidant and antitumor properties. Due to its chemical composition, it could act as an antitumor substance in the gastrointestinal tract. The objective of this study was to explore the relationship between coffee consumption and the incidence/mortality of stomach cancer in the highest-consuming countries. An ecological study using Spearman’s correlation coefficient was performed. The WorldAtlas’s dataset of coffee consumption and the incidence/mortality rates database of the International Agency for Research were used as sources of information. A total of 25 countries were entered to the study. There was an inverse linear correlation between coffee consumption in kg per person per year and estimated age-adjusted incidence (r = −0.5984, p = 0.0016) and mortality (r = −0.5877, p = 0.0020) of stomach cancer. Coffee may potentially have beneficial effects on the incidence and mortality of stomach cancer, as supported by the data from each country analyzed.

1 October 2022 in JCO Global Oncology
Verified
Journal Article
Open access
VEVanessa Eaton
Vanessa Eaton
AZAngela Zambrano
Angela Zambrano
VSValeria Sanabria
Valeria Sanabria
RLRoberto Lopez
Roberto Lopez
IKIshmael Kyei
Ishmael Kyei
RCRolando Camacho
Rolando Camacho
PURPOSE: Delivering high-quality cancer care to patients through a multidisciplinary team (MDT) care approach remains a challenge, particularly in low- and middle-income countries characterized by fragmented health systems and limited human resources for cancer care. City Cancer Challenge (C/Can) is supporting cities in low- and middle-income countries as they work to improve access to equitable quality cancer care. C/Can has developed an innovative methodology to address the MDT gap, piloted in four cities—Asunciòn, Cali, Kumasi, and Yangon. METHODS: Collaborating with a network of partners, C/Can and ASCO have developed a package of technical cooperation support focusing on two priority areas that have emerged as core needs: first developing consensus-based, city-wide patient management guidelines for the most common cancers and second, building capacity for the implementation of MDTs in institutions providing cancer care in the city. RESULTS: The real-time application of C/Can's MDT approach in Cali and Asuncion underlined the importance of engaging the right stakeholders early on and embedding MDT guidelines in local and national regulatory frameworks to achieve their sustainable uptake. The results in Cali and Asuncion were essential for informing the process in Yangon, asserting the clear benefits of city-to-city knowledge exchange. Finally, the global COVID-19 pandemic prompted a rapid adaptation of the methodology from an in-person to virtual format; the unexpected success of the virtual program in Kumasi has led to its application in subsequent C/Can cities. CONCLUSION: The application of C/Can's methodology in this first set of cities has reinforced not only the importance of both resource appropriate guidelines and a highly trained health workforce but also the need for commitment to work across institutions and disciplines.

16 May 2023 in Colombia Medica
Verified
Journal Article
Open access
PDF file
JMJuan Sebastian Moreno
Juan Sebastian Moreno
JBJuan Carlos Bravo-Ocaña
Juan Carlos Bravo-Ocaña
ARAlvaro José Riascos
Alvaro José Riascos
AZAngela Zambrano
Angela Zambrano
DMDiana Marcela Mendoza-Urbano
Diana Marcela Mendoza-Urbano
SPSergio I Prada
Sergio I Prada
Background:Pathology reports are stored as unstructured, ungrammatical, fragmented, and abbreviated free text with linguistic variability among pathologists. For this reason, tumor information extraction requires a significant human effort. Recording data in an efficient and high-quality format is essential in implementing and establishing a hospital-based cancer registry. Objective:This study aimed to describe implementing a natural language processing algorithm for oncology pathology reports. Methods:An algorithm was developed to process oncology pathology reports in Spanish to extract 20 medical descriptors. The approach is based on the successive coincidence of regular expressions. Results:The validation was performed with 140 pathological reports. The topography identification was performed manually by humans and the algorithm in all reports. The human identified morphology in 138 reports and by the algorithm in 137. The average fuzzy matching score was 68.3 for Topography and 89.5 for Morphology. Conclusion:A preliminary algorithm validation against human extraction was performed over a small set of reports with satisfactory results. This shows that a regular-expression approach can accurately and precisely extract multiple specimen attributes from free-text Spanish pathology reports. Additionally, we developed a website to facilitate collaborative validation at a larger scale which may be helpful for future research on the subject.

6 January 2023 in International Journal of Cancer
Verified
Journal Article
Closed access
AZAngela Zambrano
Angela Zambrano
FBFrancisco Javier Bonilla‐Escobar
Francisco Javier Bonilla‐Escobar
AHAlejandra Hidalgo
Alejandra Hidalgo
LPLuis Gabriel Parra‐Lara
Luis Gabriel Parra‐Lara
DMDiana Marcela Mendoza‐Urbano
Diana Marcela Mendoza‐Urbano
SQSara Gabriela Pacichana Quinayáz
Sara Gabriela Pacichana Quinayáz

23 July 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AGAna M. García
Ana M. García
LPLuis G. Parra-Lara
Luis G. Parra-Lara
DMDiana M. Mendoza-Urbano
Diana M. Mendoza-Urbano
JBJuan C. Bravo
Juan C. Bravo
AZAngela Zambrano
Angela Zambrano
Background: Mucosa melanoma is a rare condition with aggressive behavior and a less favorable prognosis compared to cutaneous melanoma. The objective of this study was to estimate the overall survival and clinical outcomes of patients diagnosed with mucosal melanoma in a Colombian hospital.Methods: A retrospective cohort study was conducted at Fundación Valle del Lili, a single center located in Cali, Colombia. Patients aged ≥ 18 years, both sexes, diagnosed with mucosal melanoma by histopathology study were included between 2010–2019. Patients who received extra-institutional treatment or whose vital status was unknown during follow-up were excluded. Demographic, clinical and laboratory data were obtained from medical records and laboratory and pathology databases. A descriptive analysis was performed. Survival analysis was conducted using the Kaplan–Meier method.Results: A total of 23 patients were included. Median age was 63 years old (IQR: 57–68) and 52.2% were woman. Clinical stage was 34.8% early, 26.1% locally advanced and 39.1% metastatic. The main primary locations were nasopharynx (30.4%), genitals (26.1%), rectum (21.7%), oral cavity (13%) and paranasal sinuses (8.7%). The majority received surgery (30.4%) and immunotherapy (26.1%) as first line treatment.Overall survival at one year was 80.8%, at three years 44.3%, and at five years 36.9%.Conclusion: Mucosal melanoma is a rare, aggressive disease with adverse oncological outcomes due to late diagnosis and limited treatment options. This study provides real-world data in a single-center of Colombia.

8 January 2020 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
EBEstefania Beltran
Estefania Beltran
Juan Esteban Garcia-RobledoJuan Esteban Garcia-Robledo
Juan Esteban Garcia-Robledo
LRLisa X. Rodríguez-Rojas
Lisa X. Rodríguez-Rojas
MRMartin Rengifo
Martin Rengifo
BPBladimir Perez
Bladimir Perez
AZAngela Zambrano
Angela Zambrano
Background: Multiple primary malignant neoplasms are not frequent but are increasing in incidence. Some of them are associated with genetic syndromes such as von Hippel-Lindau syndrome and Li-Fraumeni syndrome. Dedifferentiated liposarcoma is one of the rarest soft tissue tumors, and clear cell renal carcinoma is the most frequent kidney cancer. The concomitant presence of these tumors is extremely rare; however, some cases have been reported, none of them presenting with liposarcoma of the limbs. We report an interesting case of a patient with synchronous multiple primary tumors presenting with a very rare liposarcoma associated with renal cell carcinoma (a very rare association). A review of the literature and a collection of similar cases published previously are also provided. Case presentation: We report a case of a 62-year-old Hispanic man who presented to our institution with a left thigh mass compatible with dedifferentiated liposarcoma synchronous with metastatic clear cell renal carcinoma. Multiple treatment lines were provided with no response, with a further metastatic transformation. Genetic analysis by liquid biopsy showed some mutations that were not susceptible to targeted therapy. At the time of this report, the patient is undergoing palliative care because his nonresponsive metastatic disease persists. Conclusions: We present the first reported case of clear cell renal carcinoma synchronous with dedifferentiated liposarcoma of a limb. The association between renal cell carcinoma and dedifferentiated liposarcoma is unusual, and there are few reports of this presentation in the literature. More research about these tumors along with genetic tests needs to be performed to seek a better understanding of the fundamental basis of this rare association.